DUSP1蛋白对乳腺癌的影响:抗癌反应和对西斯丁的敏感性
Sefa Metin1, Hilal Altan1, Ergün Tercan2
1Department of Medical Pharmacology, Faculty of Medicine, University of Ankara, 06230 Ankara, Turkey.
概括
减少双特异性酶1 (DUSP1) 阻碍了三阴性乳腺癌细胞的生长和迁移. 这种降低调节通过调节p38活性来增强西斯化疗的有效性,从而提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 双特异性酸酶1 (DUSP1) 调节了线素激活蛋白激酶 (MAPK) 途径,影响癌细胞功能和化疗结果.
- 在三阴性乳腺癌 (TNBC) 中DUSP1的作用及其对治疗反应的影响需要进一步阐明.
研究的目的:
- 研究DUSP1下调对TNBC细胞增殖,迁移和瘤生长潜力的影响.
- 评估降低DUSP1对思丁敏感性和潜在分子机制的影响.
主要方法:
- 使用CRISPR/Cas9和siRNA来降低TNBC细胞中的DUSP1表达.
- 分析了MAPK家族成员 (p38,JNK,ERK1/2) 的表达和酸化水平.
- 评估了细胞增殖,迁移和瘤生长潜力.
- 评估了对西斯普拉丁的敏感性和p38活性作用.
主要成果:
- 低调DUSP1显著抑制了TNBC细胞的增殖,迁移和瘤生长潜力.
- 减少DUSP1表达增加了p38和JNK的酸化,但不是ERK1/2.2.
- 抑制DUSP1增强了西斯的抗癌疗效,主要是通过激活p38通路.
- 作为DUSP1/6抑制剂的BCI也表现出抗增殖作用,并增强了思普拉丁的作用.
结论:
- DUSP1下调调节通过抑制增殖和迁移来调节TNBC细胞中的抗癌反应.
- 向DUSP1通过调节p38活性来增强TNBC细胞,特别是MDA-MB-231对西斯的敏感性.
- 这些发现表明DUSP1作为一种潜在的治疗点,可以提高乳腺癌中西斯普拉丁治疗疗效.
相关概念视频
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:37DNA Damage can Stall the Cell Cycle
9.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K